The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Open accessAbstract
IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic medical centers in Australia, Canada, France, and the United States. Eligible patients were aged 18 years and older and had advanced or metastatic melanoma. Data were pooled from 655 enrolled patients (135 from a nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ipilimumab treated] and 520 from randomized cohorts [n = 226 ipilimumab naive; n = 294 ipilimumab treated]). Cutoff dates were April 18, 2014, for safety analyses and October 18, 2014, for efficacy analyses. EXPOSURES: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks continued until disease progression, intolerable toxicity, or investigator decision. MAIN OUTCOMES AND MEASURES: The primary end point was confirmed objective response rate (best overall response of complete response or partial response) in patients with measurable disease at baseline per independent central review. Secondary end points included toxicity, duration of response, progression-free survival, and overall survival. RESULTS: Among the 655 patients (median [range] age, 61 [18-94] years; 405 [62%] men), 581 had measurable disease at baseline. An objective response was reported in 194 of 581 patients (33% [95% CI, 30%-37%]) and in 60 of 133 treatment-naive patients (45% [95% CI, 36% to 54%]). Overall, 74% (152/205) of responses were ongoing at the time of data cutoff; 44% (90/205) of patients had response duration for at least 1 year and 79% (162/205) had response duration for at least 6 months. Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total population and 52% (95% CI, 43%-60%) among treatment-naive patients. Median overall survival in the total population was 23 months (95% CI, 20-29) with a 12-month survival rate of 66% (95% CI, 62%-69%) and a 24-month survival rate of 49% (95% CI, 44%-53%). In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not reached) with a 12-month survival rate of 73% (95% CI, 65%-79%) and a 24-month survival rate of 60% (95% CI, 51%-68%). Ninety-two of 655 patients (14%) experienced at least 1 treatment-related grade 3 or 4 adverse event (AE) and 27 of 655 (4%) patients discontinued treatment because of a treatment-related AE. Treatment-related serious AEs were reported in 59 patients (9%). There were no drug-related deaths. CONCLUSIONS AND RELEVANCE: Among patients with advanced melanoma, pembrolizumab administration was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treatment-related AEs occurred in 14%. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01295827.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [2]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“In melanoma, anti-PD-1 treatment was more effective in patients with smaller tumors (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“For example, patients with smaller tumors or low serum lactate dehydrogenase (LDH) levels at baseline have a better prognosis and are also more likely to respond to anti-PD-1 treatment (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Patients more likely to benefit from checkpoint immunotherapy include those with tumors demonstrating a high density of somatic mutations, elevated PD-L1 expression and/or are enriched with IFNγ transcriptional profiles (8–13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“Anti-PD-1 immunotherapy has shown efficacy in melanoma, but fewer than half of all melanoma patients treated with anti-PD-1 immunotherapy have a prolonged response5.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationWolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma. Lancet. 2014;384(9948):1109-1117.
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002). Lancet Oncol. 2015;16(8):908-918.
- Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size (BTS) and PD-L1 expression are independently associated with clinical outcomes in patients (pts) with metastatic melanoma (MM) treated with pembrolizumab (pembro; MK-3475). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1188.
- Kluger HM, Sznol M, Callahan MK et al. Survival, response duration and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558,ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1203.
Cited by
Sorted by citations
Items 401–500 of 1,000
Mechanisms of Resistance to Immune Checkpoint Antibodies
Ramos, R. N., Piaggio, E., & Romano, E. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_11 · Cited by 32
Epigenetic Strategies to Boost Cancer Immunotherapies
Barrero, M. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061108 · Cited by 33
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
Vâjâitu, C., DRAGHICI, C. C., Solomon, I., Lisievici, C. V., Popa, A. V., Lupu, M., Căruntu, C., Constantin, M. M., & Voiculescu, V. M. (2018) · Journal of Immunology Research · doi:10.1155/2018/4625472 · Cited by 32
DGKA Mediates Resistance to PD-1 Blockade
Fu, L., Li, S., Xiao, W., Yu, K., Li, S., Yuan, S., Shen, J., Dong, X., Fang, Z., Zhang, J., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0216 · Cited by 33
Virus-inspired strategies for cancer therapy
Yin, X., Hill, B., Hoang, T., & Wen, F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.021 · Cited by 34
Acidic and Hypoxic Microenvironment in Melanoma: Impact of Tumour Exosomes on Disease Progression
Boussadia, Z., Gambardella, A. R., Mattei, F., & Parolini, I. (2021) · Cells · doi:10.3390/cells10123311 · Cited by 33
Anti-PD-1 and PD-L1 Antibodies in Metastatic Melanoma
Simeone, E., & Ascierto, P. A. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0018 · Cited by 31
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
Cowey, C. L., Liu, F. X., Black-Shinn, J., Stevinson, K. L., Boyd, M., Frytak, J. R., & Ebbinghaus, S. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000204 · Cited by 31
Self-citationDillon, L. D., Gadzia, J. E., Davidson, R. S., McPhee, M. D., Covington, K. R., Cook, R. W., Johnson, C. E., Monzon, F. A., Milanese, E. D., Vetto, J. T., et al. (2018) · SKIN The Journal of Cutaneous Medicine · doi:10.25251/skin.2.2.3 · Cited by 31
Melanoma Immunotherapy in the Elderly
Orloff, M. M. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0656-3 · Cited by 31
Retracted: Cancer immunotherapy: challenges and clinical applications
Xia, A., Xu, Y., & Lu, X. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105852 · Cited by 30
RetractedRisk factors for the development of a second melanoma in patients with cutaneous melanoma
Pastor‐Tomás, N., Martínez‐Franco, A., Bañuls, J., Peñalver, J. C., Traves, V., García‐Casado, Z., Requena, C., Kumar, R., & Nagore, E. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16341 · Cited by 31
HOIP limits anti-tumor immunity by protecting against combined TNF and IFN-gamma-induced apoptosis
Freeman, A. J., Vervoort, S. J., Michie, J., Ramsbottom, K. M., Silke, J., Kearney, C. J., & Oliaro, J. (2021) · EMBO Reports · doi:10.15252/embr.202153391 · Cited by 31
Zhang, Z., Luo, L., Xing, C., Chen, Y., Xu, P., Mao, L., Zeng, L., Li, C., Ghosh, S., Manna, D. D., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00263-z · Cited by 31
Wenthe, J., Naseri, S., Hellström, A.-C., Moreno, R., Ullenhag, G. J., Alemany, R., Lövgren, T., Eriksson, E., & Loskog, A. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.003 · Cited by 29
He, H., Qi, X., Fu, H., Xu, J., Zheng, Q., Chen, L., Zhang, Y., Hua, H., Xu, W., Xu, Z., et al. (2023) · Theranostics · doi:10.7150/thno.87243 · Cited by 30
Santiago-Sánchez, G. S., Fabian, K. P., & Hodge, J. W. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2308097 · Cited by 31
Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
Mok, S., Liu, H., Çobanoğlu, D. A., Anang, N.-A. A. S., Mancuso, J. J., Wherry, E. J., & Allison, J. P. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2418985122 · Cited by 30
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
Zielińska, M. K., Ciążyńska, M. A., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2025) · Biomolecules · doi:10.3390/biom15020269 · Cited by 30
Bence, C., Hofman, V., Chamorey, E., Long-Mira, É., Lassalle, S., Albertini, A. F., Liolios, I., Zahaf, K., Picard, A., Montaudié, H., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16016 · Cited by 31
Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy
Andruska, N. D., Mahapatra, L., Hebbard, C., Patel, P. P., & Paul, V. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-225937 · Cited by 30
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis
Wu, Z., Sun, W., & Wang, C. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01464-w · Cited by 29
Flynn, M. J., & Larkin, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1369956 · Cited by 30
Endocrinopathies with use of cancer immunotherapies
Villa, N. M., Farahmand, A., Du, L., Yeh, M. W., Praw, S. S., Ribas, A., Chmielowski, B., Cherry, G., & Leung, A. M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13483 · Cited by 30
Self-citationAtezolizumab for the treatment of breast cancer
Basile, D., Pelizzari, G., Vitale, M. G., Lisanti, C., Cinausero, M., Iacono, D., & Puglisi, F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1469619 · Cited by 29
Hu, N., Li, W., Hong, Y., Zeng, Z., Zhang, J., Wu, X., Zhou, K., & Wu, F. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.006 · Cited by 29
Schroeder, C., Gatidis, S., Kelemen, O., Schütz, L., Bonzheim, I., Muyas, F., Martus, P., Admard, J., Armeanu–Ebinger, S., Gückel, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52923-0 · Cited by 31
Weber, J. S., Levit, L. A., Adamson, P. C., Bruinooge, S. S., Burris, H. A., Carducci, M. A., Dicker, A. P., Gönen, M., O’Keefe, S. J., Postow, M. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4692 · Cited by 28
Self-citationLelliott, E. J., Cullinane, C. M., Martin, C. A., Walker, R., Ramsbottom, K. M., Souza-Fonseca-Guimarães, F., AbuHammad, S., Michie, J., Kirby, L., Young, R. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37883-y · Cited by 30
Zhi, J., Zhang, P., Zhang, W., Ruan, X., Tian, M., Guo, S., Zhang, W., Zheng, X., Zhao, L., & Gao, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa656 · Cited by 28
Wang, Y., Zhang, X., Xie, X., Chen, W., Li, M., Diao, D., & Dang, C. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1838032 · Cited by 30
Spagnolo, F., Boutros, A., Cecchi, F., Croce, E., Tanda, E. T., & Queirolo, P. (2021) · BMC Cancer · doi:10.1186/s12885-021-08165-0 · Cited by 31
Shui, I. M., Liu, X. Q., Zhao, Q., Kim, S. T., Sun, Y. M., Yearley, J. H., Choudhury, T., Webber, A. L., Krepler, C., Cristescu, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004879 · Cited by 29
Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non–Small Cell Lung Cancer
Tamura, T., Akimoto, E., Matsumoto, C., Mori, S., Nishi, T., Kudo, K., & Kuyama, S. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.026 · Cited by 28
Clinical Correlates of Response to Anti-PD-1–based Therapy in Patients With Metastatic Melanoma
Davis, E. J., Perez, M. C., Ayoubi, N., Zhao, S., Ye, F., Wang, D. Y., Sosman, J. A., Al-Rohil, R. N., Eroglu, Z., & Johnson, D. B. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000258 · Cited by 28
Radiotherapy and immune checkpoint blockades: a snapshot in 2016
Koo, T., & Kim, I. A. (2016) · Radiation Oncology Journal · doi:10.3857/roj.2016.02033 · Cited by 27
Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance
Han, P., Dai, Q., Fan, L., Lin, H. R., Zhang, X., Li, F., & Yang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00251 · Cited by 28
Chen, X., Wang, M., Hu, Y., Gong, T., Zhang, Z., Yu, R., & Fu, Y. S. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02780g · Cited by 27
Wang, G., He, L., Wang, S., Zhang, M., Li, Y., Liu, Q., Sun, N., Zhang, X., Liu, Y., Zhang, J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa309 · Cited by 28
van Zeijl, M. C. T., Haanen, J. B. A. G., Wouters, M. W. J. M., de Wreede, L. C., Jochems, A., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., et al. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000334 · Cited by 27
Zhang, L., Li, L., Zhan, Y., Wang, J., Zhu, Z., & Zhang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.542140 · Cited by 26
Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma
Aboul‐Fettouh, N., Morse, D., Patel, J., & Migden, M. R. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.11s2a169s · Cited by 28
Bai, X., Wang, X., Ma, G., Song, J., Liu, X., Wu, X. L., Zhao, Y., Liu, X., Liu, Z., Zhang, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793831 · Cited by 27
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors
Luksik, A. S., Maxwell, R., Garzón-Muvdi, T., & Lim, M. K. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0513-3 · Cited by 27
Xu, Y., Fang, L., Jia, R., & Fan, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s162073 · Cited by 27
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
Mukherjee, N., Strosnider, A., Vagher, B., Lambert, K. A., Slaven, S., Robinson, W. A., Amato, C. M., Couts, K. L., Bemis, J. G. T., Turner, J. A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0932-z · Cited by 27
Wang, M., Chen, C., Jemielita, T., Anderson, J. R., Li, X. N., Hu, C., Kang, S. P., Ibrahim, N., & Ebbinghaus, S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0513-4 · Cited by 26
Self-citationA human receptor occupancy assay to measure anti‐PD ‐1 binding in patients with prior anti‐PD ‐1
Junker, F., Gulati, P., Wessels, U., Seeber, S., Stubenrauch, K., Deak, L. C., Markert, C., Klein, C., Teixeira, P. C., & Kao, H. (2021) · Cytometry Part A · doi:10.1002/cyto.a.24334 · Cited by 26
Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma
Luo, C., Xin, H., Yin, D., Zhao, T., Hu, Z., Zhou, Z., Sun, R., Yao, N., Sun, Q., Fan, J., et al. (2021) · Aging · doi:10.18632/aging.203076 · Cited by 26
Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs
Montisci, A., Vietri, M. T., Palmieri, V., Sala, S., Donatelli, F., & Claudio Napoli, A. (2021) · Cancers · doi:10.3390/cancers13194797 · Cited by 27
Ji, H., Liu, N., Li, J., Chen, D., Luo, D., Sun, Q., Liu, Y., Liu, Y., Bu, B., Chen, X., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz064 · Cited by 26
Zhang, C., Wang, H., Aji, T., Li, L., Li, Y., Ainiwaer, A., Rousu, Z., Li, J., Wang, M., Deng, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50754-7 · Cited by 25
Kee, D., & McArthur, G. A. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.014 · Cited by 26
Feng, Y., Dai, Y., Gong, Z., Cheng, J., Zhang, L., Sun, C., Zeng, X., Jia, Q., & Zhu, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s162729 · Cited by 25
Bartek, J. J., Alattar, A. A., Dhawan, S., Ma, J., Koga, T., Nakaji, P., Dusenbery, K. E., & Chen, C. C. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03268-y · Cited by 25
Sugisaka, J., Toi, Y., Taguri, M., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., Suzuki, K., et al. (2019) · JMA Journal · doi:10.31662/jmaj.2019-0005 · Cited by 25
Immunotherapy in breast cancer: A clinician's perspective
Chaudhuri, S., Thomas, S., & Münster, P. N. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.01.001 · Cited by 25
Zaremba, A., Philip, M., Hassel, J. C., Glutsch, V., Fiocco, Z., Loquai, C., Rafei-Shamsabadi, D. A., Gutzmer, R., Utikal, J. S., Haferkamp, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.032 · Cited by 25
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
Zhou, G., Boor, P. P. C., Bruno, M. J., Sprengers, D., & Kwekkeboom, J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01453-3 · Cited by 25
Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling
Doepner, M., Lee, I., Natale, C. A., Brathwaite, R., Venkat, S., Kim, S. H., Wei, Y., Vakoc, C. R., Capell, B. C., Katzenellenbogen, J. A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn4007 · Cited by 25
Sorroche, B. P., Teixeira, R. D. J., Pereira, C. A., Santana, I. V. V., Vujanovic, L. N., Vazquez, V. D. L., & Arantes, L. M. R. B. (2023) · Diagnostics · doi:10.3390/diagnostics13061041 · Cited by 26
Tsur, N., Kogan, Y., Rehm, M., & Agur, Z. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110033 · Cited by 26
Sun, T., Zhang, W., Li, Y., Jin, Z., Du, Y., Tian, J., & Xue, H. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0495 · Cited by 26
Wang, X., Tian, H., Chi, Z., Si, L., Sheng, X., Hu, H., Gu, X., Li, S., Li, C., Lian, B., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010662 · Cited by 25
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
Appleton, E. S., Chiocca, E. A., Ungerechts, G., Melcher, A. A., & Vile, R. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01206-1 · Cited by 24
Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer
Chen, L. L., Aria, A. B., Silapunt, S., & Migden, M. R. (2018) · Dermatologic Surgery · doi:10.1097/dss.0000000000001601 · Cited by 23
Health care utilization and steroid‐refractory toxicities from immune checkpoint inhibitors
Wang, L. X., Quach, H. T., Moodabigil, N. V., Davis, E. J., Sosman, J. A., Dusetzina, S. B., & Johnson, D. B. (2019) · Cancer · doi:10.1002/cncr.32542 · Cited by 24
MLLT6 maintains PD‐L1 expression and mediates tumor immune resistance
Sreevalsan, S., Döring, M., Paszkowski‐Rogacz, M., Brux, M., Blanck, C., Meyer, M., Momburg, F., Buchholz, F., & Theis, M. (2020) · EMBO Reports · doi:10.15252/embr.202050155 · Cited by 26
Li, L., Zeng, X., Chao, Z., Luo, J., Guan, W., Zhang, Q., Ge, Y., Wang, Y., Xiong, Z., Ma, S., et al. (2023) · Advanced Science · doi:10.1002/advs.202301975 · Cited by 23
Current Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25
Treatment of advanced melanoma - A changing landscape
Hepner, A., Salgues, A. C. R., dos Anjos, C. A., Sahade, M., de Camargo, V. P., Garicochea, B., Shoushtari, A. N., Postow, M. A., Fernandes, G. D. S., & Munhoz, R. R. (2017) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.63.09.814 · Cited by 23
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 28
Exosome and Secretion: Action On?
Hu, Y., Zhang, R., & Chen, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_19 · Cited by 25
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 30
Patient-derived tumor xenograft models for melanoma drug discovery
Harris, A. L., Joseph, R. W., & Copland, J. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1216968 · Cited by 23
Self-citationLou, Y., Marin-Acevedo, J. A., Vishnu, P., Manochakian, R., Dholaria, B., Soyano, A. E., Luo, Y., Zhang, Y., & Knutson, K. L. (2019) · Immunotherapy · doi:10.2217/imt-2018-0128 · Cited by 23
Jairath, N. K., Farha, M. W., Jairath, R., Harms, P. W., Tsoi, L. C., & Tejasvi, T. (2020) · Melanoma Management · doi:10.2217/mmt-2020-0019 · Cited by 22
Wohlmuth, C., Wieser, I., & Laframboise, S. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000583 · Cited by 23
Bollard, S. M., Casalou, C., Goh, C. Y., Tobin, D. J., Kelly, P., McCann, A. H., & Potter, S. (2020) · Pharmaceuticals · doi:10.3390/ph13120475 · Cited by 23
ACSL4-mediated lipid rafts prevent membrane rupture and inhibit immunogenic cell death in melanoma
Zhao, X., Zhao, Z., Li, B., Huan, S., Li, Z., Xie, J., & Liu, G. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07098-3 · Cited by 23
The safety of anti PD-1 therapeutics for the treatment of melanoma
Ramelyte, E., Hogan, S. A., & Dummer, R. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1248402 · Cited by 21
Yuki, T., Yoshida, T., Shibaki, R., Matsumoto, Y., Goto, Y., Kanda, S., Horinouchi, H., Yamamoto, N., Motoi, N., & Ohe, Y. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.002 · Cited by 20
The role of cellular proteostasis in antitumor immunity
Mercier, R., & LaPointe, P. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101930 · Cited by 24
Multidisciplinary approach and treatment of acral and mucosal melanoma
Fortuna, A., & Amaral, T. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1340408 · Cited by 25
New Molecular, Biological, and Immunological Agents Inducing Hypophysitis
Angelousi, A. G., Chatzellis, E., & Kaltsas, G. (2017) · Neuroendocrinology · doi:10.1159/000480086 · Cited by 22
The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series
Nguyen, M., Shah, M. H., Liebner, D. A., Backes, F. J., Phay, J. E., & Shirley, L. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7059 · Cited by 22
Overcoming Resistance Mechanisms to Melanoma Immunotherapy
Zheng, D. X., Bozym, D. J., Tarantino, G., Sullivan, R. J., Liu, D., & Jenkins, R. W. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00907-7 · Cited by 25
Serum metabolic profiling enables diagnosis, prognosis, and monitoring for brainstem gliomas
Li, K., Wang, R., Gu, Z., Weng, W., Liu, W., Huang, Y., Wu, J., Zhang, Z., Yang, S., Su, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61163-9 · Cited by 23
Wang, J., Yang, H.-R., Wang, D.-J., & Wang, X.-X. (2020) · Oncology Letters · doi:10.3892/ol.2020.12205 · Cited by 22
Lu, F., Hou, L., Wang, S., Yu, Y., Zhang, Y., Sun, L., Wang, C., Ma, Z., & Yang, F. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1927246 · Cited by 20
PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
Parakh, S., Musafer, A., Paessler, S., Witkowski, T., Suen, C. S. N. L. W., Tutuka, C. S. A., Carlino, M. S., Menzies, A. M., Scolyer, R. A., Cebon, J. S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672521 · Cited by 22
Shui, I. M., Scherrer, E., Frederickson, A. M., Li, J. W., Mynzhassarova, A., Druyts, E., & Tawbi, H. A. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000850 · Cited by 22
Haist, M., Stege, H. M., Kuske, M., Bauer, J., Klumpp, A., Grabbe, S., & Bros, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10097-z · Cited by 24
Wan, P. K.-T., Fernandes, R. A., & Seymour, L. W. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006518 · Cited by 23
Chemotherapy in pediatric brain tumor and the challenge of the blood–brain barrier
Reza, M. J., Podany, A. T., Κhan, P., Shaffer, C. L., Siddiqui, J. A., Baranowska‐Kortylewicz, J., Lê, J., Fletcher, C. V., Ether, S. A., & Avedissian, S. N. (2023) · Cancer Medicine · doi:10.1002/cam4.6647 · Cited by 22
Quandt, Z., Jacob, S. L., Fadlullah, M. Z. H., Wu, C., Wu, C., Huppert, L. A., Levine, L. S., Sison, P., Tsai, K. K., Chow, M., et al. (2024) · BJC Reports · doi:10.1038/s44276-024-00057-7 · Cited by 21
Self-citationCombinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond
Zhou, A. Y., & Johnson, D. B. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0320-y · Cited by 24
Qiu, Y., & Xu, J. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_10_19 · Cited by 21
Afzal, M. Z., Sarwar, T., & Shirai, K. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000272 · Cited by 20
Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications
Krueger, J., Rudd, C. E., & Taylor, A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101295 · Cited by 22
Metadata
- Authors
- Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B., Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P., & Robert, C.
- Affiliations
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- University of California, San Francisco (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Westmead Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- South Texas Accelerated Research Therapeutics (US)
- The University of Texas MD Anderson Cancer Center (US)
- Moffitt Cancer Center (US)
- Abramson Cancer Center (US)
- The University of Sydney (AU)
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- Institut Gustave Roussy (FR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Ribas, Antoni
- ORCID
- Ribas, Antoni
- Hamid, Omid
- Daud, Adil
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Kefford, Richard
- Joshua, Anthony M.
- Patnaik, Amita
- Hwu, Wen-Jen
- Weber, Jeffrey S.
- Hersey, Peter
- Dronca, Roxana
- Joseph, Richard W.
- Zarour, Hassane
- Chmielowski, Bartosz
- Lawrence, Donald P.
- Algazi, Alain
- Rizvi, Naiyer A.
- Mateus, Christine
- Li, Xiaoyun Nicole
- Robert, Caroline
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-19
- Volume
- 315
- Issue
- 15
- Pages
- 1600
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2338494814
- Cited by
- 1,069
- References
- 22
- Citations by year
- 2026: 33 · 2025: 66 · 2024: 67 · 2023: 99 · 2022: 63 · 2021: 123 · 2020: 139 · 2019: 139 · 2018: 145 · 2017: 153 · 2016: 39
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, advanced melanoma, metastatic melanoma, anti-PD-1 therapy, anti-PD-1 monoclonal antibody, objective response rate, overall survival, progression-free survival, duration of response, ipilimumab, immune checkpoint inhibitors, treatment-naive patients, treatment-emergent adverse events, immune-related adverse events, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Rate, Treatment Outcome, Disease Progression, Disease-Free Survival, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
